Dactolisib (BEZ235, NVP-BEZ 235)

Alias: BEZ 235; BEZ235; BEZ-235; Dactolisib; NVPBEZ235; NVP-BEZ 235; NVP-BEZ-235; NVP-BEZ235
Cat No.:V0101 Purity: ≥98%
Dactolisib (formerly also known as NVP-BEZ235; BEZ235; BEZ-235) is a novel, potent and dual ATP-competitive inhibitor of PI3K (phosphatidylinositol 3-kinase) and mTOR for p110α/γ/δ/β and mTOR(p70S6K) with anticancer activity.
Dactolisib (BEZ235, NVP-BEZ 235) Chemical Structure CAS No.: 915019-65-7
Product category: PI3K
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10mg
50mg
100mg
250mg
500mg
1g
Other Sizes

Other Forms of Dactolisib (BEZ235, NVP-BEZ 235):

  • Dactolisib tosylate
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
InvivoChem's Dactolisib (BEZ235, NVP-BEZ 235) has been cited by 1 publication
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Dactolisib (formerly also known as NVP-BEZ235; BEZ235; BEZ-235) is a novel, potent and dual ATP-competitive inhibitor of PI3K (phosphatidylinositol 3-kinase) and mTOR for p110α/γ/δ/β and mTOR(p70S6K) anticancer activity. With IC50 values of 4 nM, 5 nM, 7 nM, 75 nM, and 6 nM in cell-free assays, it inhibits mTOR for p110/// and mTOR(p70S6K). The first PI3K inhibitor to enter clinical trials was dactolisib (introduced in 2006), which exhibits strong antitumor efficacy against nonfunctioning pituitary adenomas. The IC50 value for it in 3T3TopBP1-ER cells is 21 nM, and it inhibits ATR. BEZ235 has both in vitro and in vivo evidence of potential anti-tumor activity. Regardless of the PI3K pathway mutation status, it stopped the growth of several cancer cell lines. It exhibited antitumor activity in xenograft mouse models and blocked PI3K signaling. It was shown through a combination study that temozolomide's effectiveness is increased.

Biological Activity I Assay Protocols (From Reference)
Targets
p110α (IC50 = 4 nM); p110α-H1047R (IC50 = 4.6 nM); p110α-E545K (IC50 = 5.7 nM); p110γ (IC50 = 5 nM); p110δ (IC50 = 7 nM); p110β (IC50 = 75 nM); mTOR (IC50 = 20.7 nM); mTORC1; mTORC2; Autophagy
ln Vitro
Dactolisib (BEZ235) potently inhibits PI3K in an ATP Competitive Manner. The phosphorylation levels of p70S6K, an mTOR activated kinase, were significantly lowered by the 250 nM dose of dactolisib (BEZ235). Due to the fact that the kinase domain of mTOR is highly similar to the one of class IA PI3K, Dactolisib (BEZ235) also causes a decrease in S235/S236P-RPS6 levels with an IC50 of 6.5 nM. A biochemical mTOR K-LISA assay (IC50, 20.7 nM) is used to demonstrate Dactolisib's (BEZ235) anti-mTOR activity[1].
The IC50s of Dactolisib (BEZ235) for the HCT116, DLD-1, and SW480 cell lines are 14.36.4, 9.01.5, and 12.01.6 nM, respectively[2].
ln Vivo
Dactolisib (BEZ235) (45 mg/kg, p.o.) treatment induces colonic tumor regression in a GEM model for sporadic PIK3CA wild-type CRC[2]. Dactolisib (BEZ235) is given orally to MENX rats (n=2 per group) at a dose of 45 mg/kg, and the animals are sacrificed 1 or 6 hours later. When compared to rats treated with PEG, immunostains for P-AKT and P-S6 show a significant reduction of the two proteins, particularly P-S6, 6 hours after Dactolisib (BEZ235) administration. Pituitary adenomas in Dactolisib (BEZ235)-treated rats have a proteomic profile that is significantly different from tumors in placebo-treated rats six hours after treatment[3].
Enzyme Assay
PI3Kα, β, and δ​ proteins are made up of the iSH2 domain of p85 fused to the complete protein p110, with the exception of, which likewise lacks the final 20 amino acids. Full-length PI3K proteins with the first 144 amino acids deleted are generated. For easy purification, each construct is fused to a COOH-terminal His tag before being cloned into the pBlue-Bac4.5 or pVL1393 plasmids, depending on the isoform being studied. Then, using techniques suggested by the vendor for producing the appropriate recombinant baculoviruses and proteins, the various vectors are cotransfected with BaculoGold WT genomic DNA. A Kinase-Glo assay is used to assess BEZ235's ability to inhibit PI3K. The 384-well black plate is used for the kinase reaction. The PI3K proteins (10, 25, 10, and 150 nM of p110, p110, p110, and p110, respectively) are then added to each well after it has been loaded with 50 L of test items (in 90% DMSO) and 5 L of reaction buffer containing 10 g/mL PI substrate (l-phosphatidylinositol; Avanti Polar Lipids). 5 L of 1 M ATP prepared in the reaction buffer is added to begin the reaction, which is then incubated for 60 (for p110, p110, and p110) or 120 (for p110) minutes. The addition of 10 L of Kinase-Glo buffer ends the reaction. The plates are then examined for luminescence using a Synergy 2 reader. The 384-well black plate is used for the kinase reaction. The PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to each well after it has been loaded with 50 μL of test items (in 90% DMSO) and 5 μL of reaction buffer containing 10 μg/mL PI substrate (l-phosphatidylinositol; Avanti Polar Lipids). 5 μL of 1 μM ATP prepared in the reaction buffer is added to begin the reaction, which is then incubated for 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ) minutes. The addition of 10 μL of Kinase-Glo buffer ends the reaction. The plates are then examined for luminescence using a Synergy 2 reader.
Cell Assay
The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. To account for different growth kinetics, cells are plated at various initial densities (HCT116: 3 103 cells/well, DLD-1: 5.5 103 cells/well, SW480: 4.5 103 cells/well, DLD-1 PIK3CA mutant: 7 103 cells/well, and DLD-1 PIK3CA wild-type: 9 103 cells/well). BEZ235 is added to the cells at increasing concentrations after 16 hours, and the growth medium containing the drug is changed every 24 hours. According to the manufacturer's recommendations, cell viability is measured 48 hours after the start of drug treatment and 16 hours after the initial plating using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay. Cell viability following drug treatment is compared to untreated cells that were grown for 48 hours. Cells are plated with either no BEZ235 or the maximum inhibitory dose (500 nM) for 2, 6, 24, or 48 hours before being subjected to a western blot analysis.
Animal Protocol
Mice: An oral gavage of 45 mg/kg of BEZ235 in 10% 1-methyl-2-pyrrolidone/90% PEG 300 is administered daily for 28 days to tumor-bearing Apc CKO mice or a control vehicle alone (n = 8) for treatment. Based on evidence from the literature, the recommended dose of BEZ235 is 40–50 mg/kg body weight, which has been shown to be safe and effective in treating murine tumor models. Tumor-bearing mice are sacrificed one hour after the last dose of the drug, in accordance with pharmacokinetic studies showing that the tissue concentration of NVP-BEZ235 reaches its peak one hour after administration. Utilizing calipers to measure the width, length, and height of the colonic tumor, tumors are harvested for immunohistochemistry and western blot analysis.
Rats: MENX-affected rats used. In MENX rats, BEZ235 is tested at doses of 20, 30, and 45 mg/kg. The dose of 20 mg/kg is used for further studies because the two higher doses result in a weight loss of greater than 10% after 10 days of treatment. For MRI studies, BEZ235 (20 mg/kg) or a placebo (PEG) are given orally once daily to MENX-affected rats aged 7 to 8 months who have sizeable adenomas but are otherwise healthy.
References

[1]. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7(7), 1851-1863.

[2]. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One, 2011, 6(9), e25132.

[3]. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res. 2015 Jul 15;21(14):3204-15.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C30H23N5O
Molecular Weight
469.5365
Exact Mass
469.19026
Elemental Analysis
C, 76.74; H, 4.94; N, 14.92; O, 3.41
CAS #
915019-65-7
Appearance
Solid powder
SMILES
CC(C1=CC=C(N(C2=C3C=NC4=CC=C(C5=CC6=CC=CC=C6N=C5)C=C24)C(N3C)=O)C=C1)(C)C#N
InChi Key
JOGKUKXHTYWRGZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3
Chemical Name
2-Methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile.
Synonyms
BEZ 235; BEZ235; BEZ-235; Dactolisib; NVPBEZ235; NVP-BEZ 235; NVP-BEZ-235; NVP-BEZ235
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~0.01 mg/mL (0.02 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
DMF: 18 mg/mL warming (38.33 mM)
Solubility (In Vivo)
NMP+polyethylene glycol 300 (10/90, v/v): 30mg/mL (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.1297 mL 10.6487 mL 21.2974 mL
5 mM 0.4259 mL 2.1297 mL 4.2595 mL
10 mM 0.2130 mL 1.0649 mL 2.1297 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Status Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03373903 Active
Recruiting
Drug: BEZ235
Drug: BEZ235 plus everolimus (RAD001)
Respiratory Tract Infections Restorbio Inc. November 15, 2017 Phase 2
NCT04584710 Active
Recruiting
Drug: RTB101
Drug: Placebo
Covid19 Restorbio Inc. October 13, 2020 Phase 2
Biological Data

  • BEZ235 (NVP-BEZ235, Dactolisib)


    Effect of the dual PI3K/mTOR inhibitor NVP-BEZ235 on 3D organotypic cultures of rat primary NFPA cells.


  • BEZ235 (NVP-BEZ235, Dactolisib)


    Expression of DEFB1 in human NFPAs and immortalized gonadotroph cells. Clin Cancer Res. 2015 Jul 15;21(14):3204-15.


  • BEZ235 (NVP-BEZ235, Dactolisib)

    Effect of the dual PI3K/mTOR inhibitor NVP-BEZ235 in vivo.


  • BEZ235 (NVP-BEZ235, Dactolisib)


    Expression ofDEFB1in human NFPAs and immortalized gonadotroph cells.2015 Jul 15;21(14):3204-15.


  • BEZ235 (NVP-BEZ235, Dactolisib)


    Role ofDEFB1in NET cell lines.2015 Jul 15;21(14):3204-15.


  • BEZ235 (NVP-BEZ235, Dactolisib)


    Expression ofDefb1,Tnfrsf10b, andBcl2a1in rat pituitary adenoma tissues after NVP-BEZ235 treatmentin vivo.2015 Jul 15;21(14):3204-15.

  • BEZ235 (NVP-BEZ235, Dactolisib)

  • BEZ235 (NVP-BEZ235, Dactolisib)
  • BEZ235 (NVP-BEZ235, Dactolisib)
Contact Us